Share on LinkedInShare on LinkedIn

ARTICLE · 26 OCTOBER 2026

Federal Circuit Affirms Written Description Support, Vacates Mooted Non-Obviousness Finding

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

The Federal Circuit affirmed a district court's validity findings for Exelixis's Salt Patents related to its cancer drug Cabometyx, holding that disclosure of chemical name, formula, and crystalline structure provided adequate written description support. However, the Court dismissed MSN's appeal and vacated the non-obviousness finding for the '349 Patent after Exelixis unilaterally dismissed its cross-appeal, preventing MSN from opposing the adverse judgment.

United StatesIntellectual Property

In Exelixis, Inc., v. MSN Lab’ys Private LTD., No. 2025-1236 (Fed. Cir. Aug. 31, 2026), the Federal Circuit affirmed the district court’s validity findings regarding a group of asserted patents (the “Salt Patents”) and dismissed MSN’s appeal and vacated the underlying non-obviousness finding regarding the ’349 Patent.

Exelixis sued MSN for infringement of patents related to its kidney, liver, and differentiated thyroid cancer drug, Cabometyx®. In a bench trial, the district court found sufficient written description support for the asserted claims of the Salt Patents, to which MSN conceded infringement. The district court then found that the ’349 Patent was neither infringed nor invalid for obviousness. MSN appealed, challenging both validity findings. Exelixis cross-appealed as to the ’349 Patent noninfringement finding but later dismissed its cross-appeal, rendering this judgment of noninfringement final.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from